Can Two Toolkits Make a Sustainable Business?
Executive Summary
Things went downhill for population genetics company Gemini Genomics PLC after its IPO in July 2000, the most successful public offering of a UK company that year. Less than twelve months after raising $97 million on Nasdaq (where it hoped for greater visibility than from a London listing, given the paucity of UK genomics companies), the company has been bought by the German-American Sequenom Inc., in an all-paper deal worth about $224 million . Taking into account Gemini's net assets of $81.4 million, this values its technology at less than $150 million, a far cry from the company's $450 million market capitalization at its IPO.
You may also be interested in...
EU Turns Up Heat On PFAS With Broad REACH Restriction Proposal In The Works
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Need a specific report? 1000+ reports available
Buy Reports